Notably, we showed that in primary normal and CLL B-cells, RhoA activation by CXCL12 is mediated by BTK, thus explaining the inhibitory effect of Ibrutinib of integrin affinity triggering. Here, CXCL12 is linked to B-cell chronic lymphocytic leukemia.